Key result
NPY T1128C polymorphism linked to ~65% higher rate of MI or stroke in hypertensive patients.
Why the study?
The significance of the NPY T1128C polymorphism for cardiovascular and cerebrovascular disease outcomes in hypertensive patients was unclear.
Case-Control (n=1,032)
Absolute Event Rate: 8.4% vs 5.1%
p-value: p=0.040
May signal higher event risk in hypertensives; hypothesis-generating and should not yet change practice.
OBJECTIVE: The neuropeptide Y (NPY) signal peptide polymorphism T1128C has been linked to several risk factors for cardiovascular disease. The aim of the present study was to evaluate the significance of this polymorphism for cardiovascular and cerebrovascular disease outcome. DESIGN: In a prospective study cohort, 1032 hypertensive patients (174 myocardial infarction and 170 stroke patients and 688 matched controls) were analysed for the T1128C polymorphism in the NPY gene. METHODS: The dynamic allele specific hybridization (DASH) method was used for genotyping. Serum from the same participants was analysed for total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides. RESULTS: The frequency of the NPY T1128C polymorphism was 8.4% among patients with a myocardial infarction or stroke, as compared to 5.1% in the control group (P = 0.040). The difference remained significant after adjustment for the cardiovascular risk factors age, sex, smoking status, body mass index, systolic and diastolic blood pressure, presence of diabetes, total cholesterol, HDL, LDL and triglycerides. CONCLUSIONS: The present study indicates that the NPY T1128C polymorphism is an independent predictor for myocardial infarction and stroke in a Swedish hypertensive population.
No takes yet. Share an insight, caveat, or question.
Wallerstedt et al. (2004) conducted a case-control in Hypertension (n=1,032). NPY T1128C polymorphism vs. Matched controls was evaluated on Myocardial infarction or stroke (p=0.040). The NPY T1128C polymorphism was significantly more frequent among hypertensive patients with myocardial infarction or stroke compared to matched controls (8.4% vs 5.1%; P=0.040).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: